RE: Morning All30 Apr 2021 12:54
GF123
from RNS 270820,
"....Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that it has secured funding from Innovate UK, the UK's Innovation Agency, through the 'UK Research and Innovation (UKRI) Ideas to Address COVID-19' funding strand. The funding will be used to initiate a Phase 1 clinical trial ("COVIDITY") during 2021."
Phase 1 clinical study is mentioned.
Don't think it's as you put it to,
"You obviously think the grant is sufficient for Sclp to deliver the vaccine. ."
Absolutely it's not and that was my point.
Hope this helps rebalance your understanding of the Grant.